Company intelligence / Profile preview

Zion Medical

Haifa, Israel

Ownership: Private
Development stage: Other

Overview

The company’s lead program, Gammora, demonstrated elimination of up to 99% of the HIV virus in early phase human trials with no significant side effects. The drug is currently in Phase II clinical trials for HIV/AIDS, also being tested for COVID-19 and previously for cancer. Early studies indicated increase in CD4 counts and strong antiviral effect; further validation in larger cohorts is pending.[2][3]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Synthetic peptide
Industry: Biotech

Partnerships

Mount Sinai Hospital (NYC)

Beyond the preview

Go deeper on Zion Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zion Medical.

Explore the full profile